Genetics of antipsychotic treatment emergent weight gain in schizophrenia.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Pharmacogenomics (London)

• Publication date

  2006-09-19

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.2217/14622416.7.6.863PMID 16981847
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Untitled Page

  2012cited by this paper
• Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain

  2009cited by this paper
• A Wellness Class for Inpatients with Psychotic Disorders

  2006cited by this paper
• Weight loss in overweight patients maintained on atypical antipsychotic agents

  2006cited by this paper
• The Human Obesity Gene Map: The 2005 Update

  2006cited by this paper
• Barriers to employment for people with schizophrenia.

  2006cited by this paper
• Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes

  2006cited by this paper
• Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches

  2006cited by this paper
• Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.

  2006cited by this paper
• Weight gain associated with the α2a‐adrenergic receptor −1291 C/G polymorphism and olanzapine treatment

  2006cited by this paper
• Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia

  2006cited by this paper
• Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

  2006cited by this paper
• Food Intake and Reward Mechanisms in Patients with Schizophrenia: Implications for Metabolic Disturbances and Treatment with Second-Generation Antipsychotic Agents

  2006cited by this paper
• Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.

  2006cited by this paper
• Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

  2005cited by this paper
• Mechanisms of insulin resistance in humans and possible links with inflammation.

  2005cited by this paper
• Plasma Leptin and Adiposity During Antipsychotic Treatment of Schizophrenia

  2005cited by this paper
• Sex Differences in the Subjective Tolerability of Antipsychotic Drugs

  2005cited by this paper
• The hardship of obesity: a soft-wired hypothalamus

  2005cited by this paper
• Prise de poids pharmaco-induite par les psychotropes et sa prise en charge : revue des données de la littérature

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Weight change with atypical antipsychotics in the treatment of schizophrenia

  2005cited by this paper
• The Gut and Energy Balance: Visceral Allies in the Obesity Wars

  2005cited by this paper
• Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

  2005cited by this paper
• Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation

  2005cited by this paper
• Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.

  2005cited by this paper
• An overview of the central control of weight regulation and the effect of antipsychotic medication

  2005cited by this paper
• Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders

  2005cited by this paper
• G protein polymorphisms in hypertension, atherosclerosis, and diabetes.

  2005cited by this paper
• Pharmacogenetics in drug development

  2005cited by this paper
• Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

  2005cited by this paper
• Ghrelin Plasma Levels during Psychopharmacological Treatment

  2005cited by this paper
• Brain regulation of food intake and appetite: molecules and networks

  2005cited by this paper
• Beyond energy balance: there is more to obesity than kilocalories.

  2005cited by this paper
• Obesity - an epidemic of the twenty-first century: an update for psychiatrists

  2005cited by this paper
• Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain.

  2005cited by this paper
• Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

  2005cited by this paper
• The human obesity gene map: the 2004 update.

  2005cited by this paper
• Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Obesity: a modern epidemic.

  2005cited by this paper
• Atypical antipsychotics and the burden of disease.

  2005cited by this paper
• The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.

  2005cited by this paper
• Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

  2005cited by this paper
• Metabolic and Endocrine Disturbances in Psychiatric Disorders: A Multidisciplinary Approach to Appropriate Atypical Antipsychotic Utilization

  2005cited by this paper
• Central regulation of energy balance: inputs, outputs and leptin resistance

  2005cited by this paper
• Plasma Leptin and Antipsychotic-Induced Body Weight Gain

  2005cited by this paper
• Discovery of Genetic Markers Associated with Clozapine Induced Agranulocytosis.

  2005cited by this paper
• Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus.

  2005cited by this paper
• Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes.

  2005cited by this paper
• Phenotype of schizophrenia: a review and formulation

  2005cited by this paper
• [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Activation of Cdk2-pRB-E2F1 cell cycle pathway by repeated electroconvulsive shock in the rat frontal cortex.

  2005cited by this paper
• Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

  2005cited by this paper
• The genetics of human drug response

  2005cited by this paper
• Antipsychotic‐induced weight gain

  2005cited by this paper
• Reasons for switching between antipsychotics in daily clinical practice.

  2005cited by this paper
• Is cannabis an anti‐antipsychotic? The experience in psychiatric intensive care

  2005cited by this paper
• The Association of Weight Gain and Olanzapine Plasma Concentrations

  2005influential reference
• Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

  2005cited by this paper
• Rates and Predictors of Adherence with Atypical Antipsychotic Medication: AFollow-Up Study of Adolescent Inpatients

  2005cited by this paper
• Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication.

  2005cited by this paper
• Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

  2005cited by this paper
• The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.

  2005cited by this paper
• The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

  2005cited by this paper
• How can drug addiction help us understand obesity?

  2005cited by this paper
• A prospective study of serum ghrelin levels in patients treated with clozapine

  2005cited by this paper
• The economic burden of schizophrenia in the United States in 2002.

  2005cited by this paper
• Behavioral treatment of obesity in patients taking antipsychotic medications.

  2005cited by this paper
• Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine

  2005cited by this paper
• Clozapine‐induced weight gain associated with the 5HT2C receptor −759C/T polymorphism

  2005cited by this paper
• [No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].

  2005cited by this paper
• Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.

  2005cited by this paper
• Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.

  2005cited by this paper
• Polymorphism of the adrenergic receptor alpha 2a −1291C>G genetic variation and clozapine-induced weight gain

  2005cited by this paper
• Amisulpride is an “atypical” antipsychotic associated with low weight gain

  2004cited by this paper
• Body mass index and future schizophrenia in Israeli male adolescents.

  2004cited by this paper
• Pharmacogenetics of antipsychotic-induced weight gain

  2004cited by this paper
• Psychiatric medication induced obesity: an aetiologic review

  2004cited by this paper
• Do we still believe in the dopamine hypothesis? New data bring new evidence.

  2004cited by this paper
• Obesity Wars: Molecular Progress Confronts an Expanding Epidemic

  2004cited by this paper
• [Bodyweight in inpatients with schizophrenia].

  2004cited by this paper
• Pharmacogenetics of antipsychotic-induced weight gain.

  2004influential reference
• Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

  2004cited by this paper
• Lack of association between the –759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.

  2004cited by this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Obesity as a disease: no lightweight matter

  2004cited by this paper
• Association between a G-protein β3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

  2004cited by this paper
• Atypical antipsychotic induced weight gain: pathophysiology and management.

  2004cited by this paper
• Association Study of Adrenergic β3 Receptor (Trp64Arg) and G-Protein β3 Subunit Gene (C825T) Polymorphisms and Weight Change during Clozapine Treatment

  2004cited by this paper
• A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

  2004cited by this paper
• Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.

  2004cited by this paper
• Insulin and human obesity.

  2004cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism

  2004cited by this paper
• Schizophrenia and employment

  2004cited by this paper

• Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis

  2023cites this paper
• Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain

  2023cites this paper
• Beyond the Asylum Walls: Tracing the Tapestry of Mental Health Interventions Across Eras and Cultures

  2023cites this paper
• Association study of Melanocortin-4 Receptor (rs17782313) and PKHD1 (rs2784243) variations and early incidence of obesity at the age of maturity

  2023cites this paper
• CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis

  2022cites this paper
• Association of a Single-Nucleotide Variant rs11100494 of the NPY5R Gene with Antipsychotic-Induced Metabolic Disorders

  2022cites this paper
• Leveraging genetics to improve Body Mass Index increase prediction in the first-episode of psychosis

  2022cites this paper
• Pharmacology of Drugs Used as Stimulants

  2021cites this paper
• Association of MTHFR C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index

  2021cites this paper
• Genetic Profiles Playing Opposite Roles of Pathogenesis in Schizophrenia and Glioma

  2020cites this paper
• A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)

  2020cites this paper
• Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients.

  2020cites this paper
• Pharmacogenetic Tests for Antipsychotic-Induced Weight Gain

  2019cites this paper
• Altered gene expression in antipsychotic-induced weight gain

  2019cites this paper
• Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics

  2018cites this paper
• Clinical and Biological Perspectives of Non-antipsychotic Psychotropic Medications and Weight Gain

  2018cites this paper
• Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain

  2018cites this paper
• Recommendations , Physical Health and Drug Safety Antipsychotic Dosing and Polypharmacy

  2017cites this paper
• Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia

  2017cites this paper
• Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain

  2017cites this paper
• A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain.

  2017cites this paper
• Association Between 5-HTR2C -759C/T (rs3813929) and -697G/C (rs518147) Gene Polymorphisms and Risperidone-Induced Insulin Resistance Syndrome in an Indian Population.

  2017cites this paper
• Physical Health and Drug Safety in Individuals with Schizophrenia

  2017cites this paper
• In silico Prioritization of Genetic Risk Variants Using Functional Genomic Information

  2016cites this paper
• Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease

  2016cites this paper
• Association of orexin receptor polymorphisms with antipsychotic-induced weight gain

  2016cites this paper
• Association Study of 60 Candidate Genes with Antipsychotic-induced Weight Gain in Schizophrenia Patients

  2016cites this paper
• WEIGHT GAIN AND ANTIPSYCHOTICS. DATA FROM EUFEST STUDY.

  2016cites this paper
• Genetics of Common Antipsychotic-Induced Adverse Effects

  2016cites this paper
• Featured Article Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease

  2016cites this paper
• Einfluss von Neuropeptid Y-Genvarianten auf die antipsychotika- induzierte Gewichtszunahme bei Patienten mit Schizophrenie

  2015cites this paper
• DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain.

  2015cites this paper
• Association Study of GABAA &agr;2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain

  2015cites this paper
• DNA methylation in psychosis: insights into etiology and treatment.

  2015cites this paper
• The Role of Leptin-Melanocortin System Gene Variants in Antipsychotic-Induced Weight Gain

  2015cites this paper
• Examining treatment response and adverse effects of clozapine

  2015cites this paper
• The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain

  2015cites this paper
• A2BP1 gene polymorphisms association with olanzapine-induced weight gain.

  2015cites this paper
• A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population.

  2015cites this paper
• The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum

  2014cites this paper
• Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight

  2014cites this paper
• Pharmacogenetics of Antipsychotics

  2014cites this paper
• A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia

  2014cites this paper
• Leptin -2548g/a gene polymorphism in association with antipsychotic-induced weight gain: a meta-analysis study.

  2014cites this paper
• Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.

  2014cites this paper
• Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

  2014cites this paper
• Aus der Klinik für Psychiatrie und Psychotherapie

  2014cites this paper
• Pharmacogenetics of the G protein-coupled receptors.

  2014cites this paper
• HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: A meta-analysis

  2014cites this paper
• Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed

  2014cites this paper
• Protein kinase cAMP‐dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic‐induced weight gain

  2014cites this paper
• Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

  2014cites this paper
• Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.

  2014cites this paper
• Pharmakogenetische Untersuchungen psychiatrischer Patienten: Bestimmung ausgewählter genetischer Varianten in pharmakokinetischen und pharmakodynamischen Strukturen und deren Bedeutung für die Psychopharmakotherapie

  2014cites this paper
• Personalized medicine in psychiatry: problems and promises

  2013cites this paper
• Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.

  2013cites this paper
• 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment

  2013cites this paper
• Genome-wide association of single-nucleotide polymorphisms with weight loss outcomes after Roux-en-Y gastric bypass surgery.

  2013cites this paper
• Genetics of antipsychotic-induced weight gain: update and current perspectives.

  2013cites this paper
• Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain

  2013influential citation
• The prevalence of metabolic syndrome and its associated factors in long-term patients in a specialist psychiatric hospital in South Africa.

  2013cites this paper
• Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population.

  2013cites this paper
• Antipsychotic medications, glutamate, and cell death: a hidden, but common medication side effect?

  2013cites this paper
• Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD ΙΙ

  2013cites this paper
• Crosstalk between 5-HT2cR and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction.

  2013cites this paper
• Atypical antipsychotics and diabetic ketoacidosis: a review

  2013cites this paper
• Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications

  2012cites this paper
• Poster #13 RECEPTOR BINDING PROFILES OF ANTIPSYCHOTIC MEDICATIONS AND GLUCOSE DYSREGULATION: AN ACUTE ANIMAL MODEL

  2012cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• 5‐HT2C and 5‐HT6 Receptor Targeted Emerging Approaches in Schizophrenia

  2012cites this paper
• 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.

  2012cites this paper
• Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain.

  2012cites this paper
• Obesity and Psychotropics

  2012cites this paper
• Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics

  2012cites this paper
• Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

  2012cites this paper
• The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain.

  2012cites this paper
• Genetic determinants for metabolic abnormalities

  2012cites this paper
• Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain.

  2012cites this paper
• Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first‐episode schizophrenia through 52 weeks follow‐up in China

  2012cites this paper
• Mécanismes cellulaires de l'induction du facteur de transcription Nur77 après un traitement aux antipsychotiques

  2012cites this paper
• An index of relative central α-adrenergic receptor antagonism by antipsychotic medications.

  2011cites this paper
• Association Study of Brain-Derived Neurotrophic Factor Gene Polymorphisms and Body Weight Change in Schizophrenic Patients Under Long-Term Atypical Antipsychotic Treatment

  2011cites this paper
• Genes and Human Obesity

  2011cites this paper
• Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review.

  2011cites this paper
• Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain

  2011cites this paper
• Genetics of Antipsychotic-induced Side Effects and Agranulocytosis

  2011cites this paper
• Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

  2011cites this paper
• Polymorphisms of INSIG2, MC4R, and LEP Are Associated With Obesity- and Metabolic-Related Traits in Schizophrenic Patients

  2011cites this paper
• Mechanisms and Genetics of Antipsychotic‐Associated Weight Gain

  2011cites this paper
• Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia

  2011cites this paper
• Genetic interactions in the adrenergic system genes: analysis of antipsychotic‐induced weight gain

  2011cites this paper
• Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients.

  2010cites this paper
• Endocannabinoid Pro129Thr FAAH Functional Polymorphism But Not 1359G/A CNR1 Polymorphism Is Associated With Antipsychotic-Induced Weight Gain

  2010cites this paper
• Pharmacogenetics of antipsychotic treatment response and side effects.

  2010cites this paper
• Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

  2010cites this paper
• Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment

  2010cites this paper
• A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia

  2010cites this paper
• Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain

  2010cites this paper
• Pharmacogenetic considerations in the treatment of psychiatric disorders

  2010cites this paper
• Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

  2010cites this paper